Verrica Pharmaceuticals, Inc. (VRCA)
4.28
+0.10
(+2.39%)
USD |
NASDAQ |
Oct 09, 14:21
Verrica Pharmaceuticals Gross Profit Margin (Quarterly) : 85.02% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 85.02% |
| March 31, 2026 | 82.30% |
| December 31, 2025 | 72.49% |
| September 30, 2025 | 92.27% |
| June 30, 2025 | 96.11% |
| March 31, 2025 | 87.29% |
| December 31, 2024 | -81.69% |
| September 30, 2024 | |
| June 30, 2024 | 89.53% |
| March 31, 2024 | 70.26% |
| December 31, 2023 | 80.86% |
| Date | Value |
|---|---|
| September 30, 2023 | 90.74% |
| June 30, 2023 | -88.46% |
| March 31, 2023 | -629.7% |
| December 31, 2022 | -286.8% |
| September 30, 2022 | 97.64% |
| June 30, 2022 | 23.83% |
| March 31, 2022 | 63.34% |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.47K% |
| Return on Assets | -77.06% |
| Return on Invested Capital | -173.1% |
| Profit Margin (Quarterly) | -224.4% |
| Operating Margin (Quarterly) | -194.5% |
| Return on Net Operating Assets | -222.3% |